Bellerophon Therapeutics (NSDQ:BLPH) said today that it inked a deal with new and existing investors to raise $23.4 million in a private placement of common stocks and warrants. The financing was led by Puissance Capital Management and Venrock Healthcare Capital Partners, supported by existing investors like New Mountain Capital and Linde North America, the Warren, N.J.-based […]
Funding Roundup
Engage Therapeutics raises $23m Series A for drug-device seizure therapy
Summit, N.J.-based Engage Therapeutics said today that it closed a $23 million Series A round to fund a Phase IIb trial of its lead product, Staccato alprazolam. The round was led by TPG Biotech, Adage Capital Management and Lumira Capital. The drug-device product combines a hand-held inhaler technology, which is FDA-approved, with alprazolam, an FDA-approved […]
Aspire Capital to acquire $20m worth of Valeritas stock
Valeritas (NSDQ:VLRX) said today that it inked a deal with Aspire Capital Fund to buy $20 million of Valeritas’ common stock. According to the deal, Aspire Capital is slated to purchase common stock at Valeritas’ request from time to time during a 30-month period at prices based on the market price at the time of each […]
Catalent floats $250m public offering to fund Cook Pharmica purchase
Catalent said today that it launched an underwritten public offering for $250 million of its common stock to fund, in part, its $950 million purchase of biologics manufacturer Cook Pharmica. In connection with the offering, Catalent is slated to grant underwriters a 3o-day option to buy up to $37.5 million of additional shares of common […]
Delcath deal with investors raises $500k, clears path for reverse split
Delcath Systems (NSDQ:DCTH) and a group of investors made an end run around the company’s shareholders with a deal that paves the way for the reverse split that stockowners have twice shot down. “Together with our Board of Directors, we are taking these actions in the best interests of all shareholders. Regaining access to equity capital […]
Micell raises $62m for MiStent SES
Micell Technologies said last week that it raised a debt-and-equity round worth nearly $62 million from a syndicate of 51 unnamed investors. Paris-based Micell makes the MiStent SES sirolimus-eluting absorbable polymer coronary stent, designed to treat coronary artery disease. The company, which reported a nearly $26 million round last November, said in a regulatory filing that the […]
LifeMine Therapeutics combines AI, drug discovery & microbes with $55m launch
Backed by the likes of Google and Merck (NYSE:MRK), Cambridge, Mass.-based LifeMine Therapeutics launched today by closing a $55 million Series A round. The company calls itself the first to “massively scale the genomic discovery of powerful new drugs from eukaryotic microbes”. LifeMine plans to use artificial intelligence to hunt down drugs hidden within the DNA […]
Oral drug delivery startup raises $39m for robotic pill
San Jose, Calif.-based Rani Therapeutics has some seriously big-name backers: Alphabet (NSDQ:GOOGL), Novartis (NYSE:NVS) and AstraZeneca (NYSE:AZN) have all invested in the startup. This month, the company raised $38.7 million as part of a $126.5 million offering of equity and options or warrants, according to an SEC filing. So far, 12 investors have contributed to the offering. Rani […]
Tandem Diabetes Care shareholders approve reverse split
Tandem Diabetes Care (NSDQ:TNDM) shareholders met yesterday and approved a proposal to effect a reverse stock split at a ratio between 1-for-8 and 1-for-12, according to a regulatory document. In a statement filed with the SEC in July, the San Diego, Calif.-based company told shareholders that it believed a reverse stock split would help Tandem keep […]
Merck leads $11m round for Antidote’s trial-matching tech
Antidote Technologies said today that it inked an $11 million funding round to advance its clinical trial matching technologies. The round was led by Merck’s Global Health Innovation Fund. Existing investors Smedvig Capital and Octopus Ventures participated in the round, which is contingent upon obtaining certain regulatory clearances and is expected to close later this […]